September 2026: TGA Classifies 6-Methylnicotine as a Schedule 9 Prohibited Substance to Close E-Cigarette Loophole
Australia’s Therapeutic Goods Administration (TGA) has officially decided to list 6-methylnicotine as a Schedule 9 Prohibited Substance in the Poisons Standard, with an implementation date set for October 1, 2026. This regulatory action directly targets the rapid emergence of synthetic nicotine analogues in electronic cigarettes and oral pouches, where the substance has been increasingly substituted for nicotine to circumvent strict Australian vaping controls and customs inspections.
Chemical and health findings indicate that 6-methylnicotine is a highly potent synthetic derivative with no recognized therapeutic benefit. The compound exhibits a higher binding affinity for nicotinic acetylcholine receptors and up to three times the psychotropic potency of standard nicotine, alongside greater cellular toxicity at comparable doses. Furthermore, product testing revealed significant discrepancies between labelled strengths and actual chemical concentrations, creating a substantial risk of accidental over-exposure and acute toxicity for consumers using these products.
In finalizing the decision to classify 6-methylnicotine under Schedule 9 rather than as a Schedule 7 Dangerous Poison, the TGA Delegate highlighted the need for the strongest possible regulatory framework. A Schedule 9 listing allows Commonwealth and state authorities to enforce higher legal penalties for unlawful possession, import, and distribution. This decision was driven by the acute toxicity of the compound, its presence in unapproved consumer goods, deceptive marketing that presents products as “nicotine-free” alternatives, and the high potential for dependence among youth and vulnerable groups. Because there are no approved or lawful products containing 6-methylnicotine in Australia, this scheduling classification effectively closes the regulatory loophole exploited by manufacturers.
September 2026: Australian Government Overhauls Illicit Tobacco Laws to Simplify Prosecutions
The Australian Government has introduced legislative reforms targeting the nation’s illicit tobacco trade, significantly lowering the legal hurdles required to prosecute illicit-market operators and seize assets from organized crime syndicates. Under the new legislation introduced by Assistant Minister for Customs, law enforcement agencies and Commonwealth prosecutors will no longer need to prove an offender’s subjective knowledge that imported tobacco was subject to unpaid customs duties, nor demonstrate explicit intent to defraud public revenue.
Historically, prosecutions under the Customs Act 1901 were complicated by strict evidentiary burdens requiring direct proof that suspects knowingly handled illegal imports. The amended framework introduces an objective reasonable suspicion standard, allowing prosecutors to establish that tobacco products are unlawful based on observable commercial indicators. Under these rules, prosecutors can point to retail prices set below mandatory excise duty and GST values, packaging that violates plain-packaging mandates or includes prohibited variants like menthol, or a complete lack of legitimate chain-of-custody documentation and tax invoices detailing the product’s origin.
The legislation targets the entire supply chain, extending liability beyond high-level syndicate leaders to mid-tier distributors, logistics warehouses, and retail smoke shops selling under-the-counter contraband. Alongside changes to customs prosecution rules, the bill strengthens powers under the Proceeds of Crime Act 2002. Financial investigators gain expanded authority to compel documentation and restrain property, accelerating the confiscation of cash, real estate, vehicles, and luxury goods purchased through illicit-market profits.
The crackdown arrives amid a broader debate in Parliament over tobacco taxation. The Opposition has proposed an 80% reduction in legal tobacco excise – which would lower the tax on a standard 20-pack by A$24 – arguing that high taxes have fueled consumer demand for criminal suppliers. The Coalition has also advocated for legalizing and taxing adult nicotine vapes while directing A$200 million toward enforcement, while One Nation has separately called for a 75% excise cut. The Labor government has maintained its opposition to steep excise cuts, arguing that high taxes remain a cornerstone of national public health strategy and that targeted enforcement and financial forfeiture represent the most effective tools to dismantle criminal distribution networks.
September 2026: Australian Coalition Proposes 80% Tobacco Tax Cut to Smash Illicit Cigarette Market
Australia’s federal Opposition Coalition has unveiled a policy to slash the national tobacco excise by 80%, proposing a dramatic tax cut designed to destroy the profit margins driving the country’s rampant illicit tobacco market. Under the proposal, excise tax on a standard pack of 20 cigarettes would drop from roughly $30 to about $6, bringing retail prices down from over $40 to around $9 or $10 per pack to match black-market rates. The package also includes legalizing and taxing adult sales of e-cigarettes and nicotine pouches – dismantling the government’s current pharmacy-only model – and deploying $200 million in federal law enforcement funding to combat illegal storefronts, organized crime, and border smuggling.
Parliamentary Budget Office modeling cited by the Coalition estimates the plan could generate an additional $8 billion in tax receipts over four years by shifting consumers from illicit channels back into the taxed legal market. The proposal follows escalating arson, extortion, and gang violence linked to underground tobacco networks across major Australian cities. Opposition Leader argued that years of aggressive excise increases created a vast price gap that allowed illegal sales to capture up to 80% of total market consumption, creating a law enforcement crisis that policing alone cannot contain.
In Australian politics, the Coalition is a dominant center-right force representing the official federal Opposition. It is a permanent alliance between the urban-focused Liberal Party of Australia and the regional-focused National Party of Australia. Because Australia operates under a traditional two-party system where power alternates between the Coalition and the center-left Australian Labor Party, the Coalition’s policy announcements serve as the official alternative legislative program to the sitting government.
October 2024: Australia Expands Pharmacy-Based Vaping Model with New Access Rules
Australia implemented further changes to its vaping framework, refining its pharmacy-only access model as part of a broader effort to reduce youth uptake while maintaining vaping as a smoking cessation tool. The adjustments build on a series of regulatory reforms introduced over 2023-2024 that progressively tightened control over imports, retail supply, and product classification.
Under the new rules, pharmacists are now permitted to sell low-strength nicotine vapes (up to 2% nicotine concentration) to adults without requiring a prescription. However, access to higher-strength nicotine products remains more tightly controlled: these continue to require a prescription for purchase from pharmacies. Minors under 18 are also required to have a prescription in order to access any vaping products via the pharmacy channel.
These changes represent a further evolution of the model introduced earlier in 2024, when all nicotine vaping products were subject to a prescription requirement at pharmacy level. The October update therefore introduces a partial relaxation for adult consumers while preserving tighter safeguards for higher-risk use cases and younger individuals.
The reforms are part of Australia’s broader strategy to reposition vaping as a regulated therapeutic aid rather than a consumer product. Policymakers have consistently emphasised the need to strike a balance between supporting adult smokers seeking to quit and addressing rising concerns around youth vaping.
The regulatory backdrop reflects a longer trajectory of tightening controls. Since emerging in Australia around 2007, vaping has grown in popularity – particularly after 2016 – despite nicotine vaping products never having been legal for general retail sale without a prescription. Legally, only pharmacists and medical practitioners have been permitted to supply nicotine-containing vapes.
At the same time, enforcement challenges have persisted. While nicotine-free vapes were previously available in retail outlets under tobacco-style restrictions (including age limits), many retailers were found to be illegally supplying nicotine-containing products. Illicit distribution has also occurred through online platforms, social media channels, messaging apps, and informal personal networks, including friends and family – particularly among younger users.
The October 2024 changes sit within a broader tightening sequence. On January 1, 2024, Australia banned the importation of disposable vapes, regardless of nicotine content. From July 1, 2024, all vaping products were formally reclassified as therapeutic goods, restricting legal sales to pharmacies only and effectively removing tobacconists, convenience stores, and other retail outlets from the market.
Taken together, these measures underscore Australia’s increasingly restrictive stance on vaping, combining tight supply controls with a regulated medical pathway intended to reduce youth access while preserving a controlled option for smoking cessation among adults.
June 2024: Australia Softens Vape Prescription Model While Retaining Pharmacy-Only Sales
The Australia government revised its proposed vaping legislation to secure parliamentary support, including backing from the Greens in the Senate1. The adjustments mark a notable shift from an earlier prescription-only model toward a pharmacy-based access system, while still maintaining some of the strictest retail controls globally.
Under the revised framework, Australia will proceed with its plan to become the first country to restrict the retail sale of nicotine vaping products exclusively to pharmacies. However, in a key policy adjustment, the government will no longer require a doctor’s prescription for access. Instead, nicotine vapes will be classified as “pharmacist-only” products, regulated similarly to behind-the-counter medicines that can be dispensed at the professional discretion of a pharmacist.
The legislative package also introduces tougher enforcement provisions targeting the illicit market. Significant penalties will apply to unlicensed retailers selling vaping products outside the regulated pharmacy system. The reforms are expected to be debated and voted on in Parliament shortly, with the ban on non-pharmacy retail sales scheduled to take effect in early July 2024.
A further change involves the down-scheduling of nicotine vaping products. While prescriptions will initially remain part of the framework, the requirement is expected to be removed from October 2024, allowing consumers to access nicotine vapes directly from pharmacies without a doctor’s prescription.
Despite the relaxation of the prescription requirement, strict product controls will remain in place. Vapes sold in pharmacies will be subject to plain packaging requirements, and flavour options will be tightly limited to mint, menthol, or tobacco. These restrictions are intended to reduce product appeal, particularly among younger users, while preserving a controlled pathway for smoking cessation.
In public comments, the Australian Health Minister described the legislation as “world-leading,” arguing that it restores vaping to its intended role as a therapeutic aid for “hardened smokers” seeking to quit, while simultaneously reducing youth exposure to recreational vaping products. The framework will also be subject to a statutory review within three years, allowing policymakers to reassess its effectiveness and make further adjustments if required.
November 2023: Australia Tightens Vaping Controls with Import Ban and Pharmaceutical Framework
Australia unveiled a strengthened regulatory package to address what policymakers described as a “new generation of nicotine dependency.” The initiative builds on earlier restrictions introduced in 2021, which required a medical prescription to legally access vaping products. Despite these controls, government data for Q1 2023 indicated persistent uptake among younger populations, with approximately one in seven individuals aged 14-17 and one in five aged 18-24 reported to be vaping.
The updated framework2 significantly tightens controls on the importation, manufacture, and supply of vaping products. From January 1, 2024, the importation of disposable vapes is banned outright, targeting a segment widely viewed as a key driver of youth experimentation due to its accessibility and convenience.
From March 1, 2024, further measures come into force. Importers and manufacturers of therapeutic vapes – products available only via prescription – are required to submit pre-market notifications to the Therapeutic Goods Administration before supplying products to the market. In parallel, personal importation of vapes is prohibited, closing a key channel through which consumers had previously accessed products outside the regulated system. Authorities, including the Office of Drug Control, have been preparing the necessary compliance infrastructure, including notification processes and licensing requirements.
Product standards for therapeutic vapes are also being strengthened. These include tighter restrictions on flavours, limits on nicotine concentrations, and the introduction of plain, pharmaceutical-style packaging. A transition period is предусмотрен to allow businesses time to align with the new requirements.
To support enforcement, the government has committed additional funding of A$25 million to the Australian Border Force and A$56.9 million to the Therapeutic Goods Administration over a two-year period. This investment is aimed at curbing illicit trade and ensuring compliance across the supply chain. Overall, the reforms reinforce Australia’s increasingly restrictive stance on vaping, with a clear emphasis on limiting access outside medical channels while addressing the continued rise in youth usage.
September 2023: Australia Moves to Tighten Tobacco and Vaping Laws with Sweeping New Measures
A comprehensive package of legislative reforms, aimed at strengthening the country’s approach to tobacco control and curbing the rapid rise in vaping, is presented to the Australian Parliament. The proposals, led by the Australian Government Department of Health and Aged Care, signal a significant escalation in regulatory oversight, extending existing tobacco-style restrictions to newer nicotine products.
A central pillar of the reform is the integration of e-cigarettes into Australia’s tobacco control framework. This would subject vaping products to the same stringent rules that apply to combustible cigarettes, including tight restrictions on advertising, promotion, and sponsorship. The move reflects growing concern among policymakers about youth uptake and the perceived normalization of vaping.
The legislative package also introduces several product-level interventions designed to reduce the appeal and perceived attractiveness of tobacco products. These include the introduction of graphic health warnings printed directly on individual cigarettes, a measure intended to reinforce health messaging at the point of consumption. In addition, the use of certain additives – such as menthol – is set to be prohibited, aligning with broader international trends targeting flavourings that may facilitate initiation.
Further standardization measures are proposed across packaging and product design. Pack sizes, product formats, and even filter characteristics would be regulated more tightly to limit differentiation and branding opportunities. The reforms also seek to eliminate descriptors or product names that could imply reduced harm, closing another avenue through which consumers might be misled about relative risks. To complement these restrictions, tobacco packaging would be required to include health promotion inserts, providing cessation information and reinforcing public health messaging directly within the pack.
If passed, the legislation is expected to come into force in April 2024. Overall, the proposal represents one of the most far-reaching updates to Australia’s tobacco control regime in recent years, underscoring a clear policy direction toward stricter regulation of both traditional and next-generation nicotine products.
May 2023: Australia Targets Recreational Vaping with Import Ban and Pharmaceutical-Style Controls
Australia announced a sweeping package of measures aimed at curbing recreational vaping and repositioning e-cigarettes within a more tightly controlled, therapeutic framework. The reforms, led by the Australian Government Department of Health and Aged Care, reflect growing concern over rising youth uptake and the proliferation of unregulated products in the market.
A central pillar of the policy is a ban on the importation of non-prescription vapes. Under the proposed system, access to vaping products would be limited to a medical pathway, effectively restricting availability to individuals with a valid prescription. This marks a decisive shift away from consumer-oriented retail toward a model more closely aligned with pharmaceutical regulation.
In parallel, the government plans to mandate pharmaceutical-style packaging for all permitted vaping products. This would significantly reduce branding and visual appeal, reinforcing the positioning of e-cigarettes as therapeutic tools rather than lifestyle or recreational products. The measures also include a comprehensive ban on single-use (disposable) vapes, which policymakers view as a major driver of youth experimentation due to their low cost, convenience, and wide availability.
Taken together, these reforms represent one of the most stringent approaches to vaping globally. They underscore Australia’s broader public health strategy: limiting nicotine product use outside strictly regulated channels while continuing to prioritize reductions in smoking prevalence.
